Abstract
Fluorodeoxyglucose positron emission tomography (FDG-PET) studies report characteristic patterns of cerebral hypometabolism in probable Alzheimer's disease (pAD) and amnestic mild cognitive impairment (aMCI). This study aims to characterize the consistency of regional hypometabolism in pAD and aMCI patients enrolled in the AD neuroimaging initiative (ADNI) using statistical parametric mapping (SPM) and bootstrap resampling, and to compare bootstrap-based reliability index to the commonly used type-I error approach with or without correction for multiple comparisons. Batched SPM5 was run for each of 1000 bootstrap iterations to compare FDG-PET images from 74 pAD and 142 aMCI patients, respectively, to 82 normal controls. Maps of the hypometabolic voxels detected for at least a specific percentage of times over the 1000 runs were examined and compared to an overlap of the hypometabolic maps obtained from 3 randomly partitioned independent sub-datasets. The results from the bootstrap derived reliability of regional hypometabolism in the overall data set were similar to that observed in each of the three non-overlapping sub-sets using family-wise error. Strong but non-linear association was found between the bootstrap-based reliability index and the type-I error. For threshold p=0.0005, pAD was associated with extensive hypometabolic voxels in the posterior cingulate/precuneus and parietotemporal regions with reliability between 90% and 100%. Bootstrap analysis provides an alternative to the parametric family-wise error approach used to examine consistency of hypometabolic brain voxels in pAD and aMCI patients. These results provide a foundation for the use of bootstrap analysis characterize statistical ROIs or search regions in both cross-sectional and longitudinal FDG-PET studies. This approach offers promise in the early detection and tracking of AD, the evaluation of AD-modifying treatments, and other biologically or clinical important measurements using brain images and voxel-based data analysis techniques.
MeSH Terms
Aged
Aged, 80 and over
Alzheimer Disease/diagnostic imaging,metabolism
Amnesia/diagnostic imaging,metabolism
Brain/diagnostic imaging,metabolism
Brain Mapping/methods
Cognition Disorders/diagnostic imaging,metabolism
Female
Humans
Image Processing, Computer-Assisted
Male
Middle Aged
Positron-Emission Tomography/methods
Reproducibility of Results
Authors & Affiliations
19 authors, click to expand affiliations / ORCID
Wu Xia
School of Information Science and Technology, Beijing Normal University, Beijing, PR China.
Chen Kewei
Yao Li
Ayutyanont Napatkamon
Langbaum Jessica B S
Fleisher Adam
Reschke Cole
Lee Wendy
Liu Xiaofen
Alexander Gene E
Bandy Dan
Foster Norman L
Thompson Paul M
Harvey Danielle J
Weiner Michael W
Koeppe Robert A
Jagust William J
Reiman Eric M
Alzheimer's Disease Neuroimaging Initiative
References (15)
15 references, click to expand
-
Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative.
Neuroimage. 2010 Jun;51(2):654-64
PMID: 20202480
-
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Alzheimers Dement. 2005 Jul;1(1):55-66
PMID: 17476317
-
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.
N Engl J Med. 1996 Mar 21;334(12):752-8
PMID: 8592548
-
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3334-9
PMID: 11248079
-
FDG PET imaging in patients with pathologically verified dementia.
J Nucl Med. 2000 Nov;41(11):1920-8
PMID: 11079505
-
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.
Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8299-302
PMID: 15932949
-
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
Neurology. 1984 Jul;34(7):939-44
PMID: 6610841
-
Alzheimer's disease: focal cortical changes shown by positron emission tomography.
Neurology. 1983 Aug;33(8):961-5
PMID: 6603596
-
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9
PMID: 14688411
-
18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans.
Can J Neurol Sci. 1990 Feb;17(1):1-11
PMID: 2311010
-
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
JAMA. 2001 Nov 7;286(17):2120-7
PMID: 11694153
-
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Neuroimage. 2009 May 1;45(4):1107-16
PMID: 19349228
-
Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease.
Neurology. 1998 Jun;50(6):1585-93
PMID: 9633698
-
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
Am J Psychiatry. 2002 May;159(5):738-45
PMID: 11986126
-
Current concepts in mild cognitive impairment.
Arch Neurol. 2001 Dec;58(12):1985-92
PMID: 11735772